Novartis gets final EC nod for Votubia

Novartis ($NVS) has won European approval for Votubia as a treatment for a rare type of brain tumor known as subependymal giant cell astrocytoma associated with tuberous sclerosis complex. With the same active ingredient as the kidney cancer drug Afinitor, Votubia is the first drug approved for these tumors. Release | Report

Suggested Articles

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease..

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opidivo has broken through with two potentially practice-changing trials.

The custodial measure came after Chinese customs officials raided Genscript’s businesses for “suspected violations of import and export regulations.”